newsfilter
← Earnings
Earnings Releases·

Harmony Biosciences — Q3 2026 Earnings Summary

  • WAKIX net revenue grew 12% year-over-year to $268.9 million in Q3 2026, though net income declined 5% to $48.2 million ($0.81/share) due to increased milestone and royalty charges; full-year 2026 revenue guidance remains reiterated at $1.0 billion to $1.04 billion.
  • The company maintains a robust liquidity position with $1.05 billion in cash and investments as of September 30, 2026, while advancing a diversified pipeline with key data readouts for BP-205, Pitolisant GR, and EPX-100 expected between Q1 2027 and mid-2027.
  • Leadership transition is scheduled for January 1, 2027, with Peter Anastasiou succeeding Jeffrey Dayno as President and CEO, while the firm continues to assert intellectual property rights to secure WAKIX exclusivity through March 2030.
  • Strategic focus remains on R&D investment in BP-205 and business development opportunities across CNS indications, supported by a patent portfolio covering amorphous pitolisant through 2042.
Company
HARMONY BIOSCIENCES HOLDINGS INC
Sector
Healthcare
Industry
Biotechnology